查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1867925

mRNA癌症疫苗和療法：全球市場佔有率和排名、總收入和需求預測（2025-2031年）

mRNA Cancer Vaccines and Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 83 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年全球 mRNA 癌症疫苗和療法的市場規模估計為 91.98 億美元，預計到 2031 年將達到 110.32 億美元，2025 年至 2031 年的複合年成長率為 5.0%。

mRNA癌症疫苗和療法是基於傳訊RNA（mRNA）技術的新型腫瘤免疫療法。此方法透過設計和遞送編碼腫瘤相關抗原的mRNA分子，使患者的免疫系統能夠識別並攻擊癌細胞，從而產生精準有效的抗癌反應。與傳統癌症療法相比，mRNA技術具有研發週期短、生產靈活、更易於個人化治療等優勢，顯著提高了治療的安全性和有效性。隨著生物製藥和基因編輯技術的快速發展，mRNA癌症疫苗和療法已成為腫瘤免疫學領域的重大突破，引領癌症治療進入精準免疫治療時代。

全球癌症發生率和死亡率的不斷攀升，迫切需要創新治療方法來改善治療效果和提高患者存活率。主要生物製藥公司的年度報告強調，他們持續投資於mRNA技術平台，加速癌症疫苗和療法的研發，同時確保其安全性和有效性。政府透過政策和資金支持，加速臨床試驗進程，並促進市場進入。 mRNA技術的靈活性及其個人化治療的潛力，能夠滿足不同類型癌症和患者群體的需求，尤其在難治性和復發性癌症方面展現出巨大的潛力。全球人口老化和精準醫療概念的廣泛應用，進一步推動了該市場的快速成長。

儘管市場潛力巨大，但挑戰依然存在。複雜且成本高昂的研發流程和漫長的檢驗期增加了開發風險。法規環境瞬息萬變，各國不同的核准標準和途徑使國際商業化進程更加複雜。高昂的研發和生產成本推高了治療費用，並限制了部分地區病患的用藥機會。激烈的市場競爭以及傳統免疫療法與新興免疫療法之間的複雜相互作用，要求企業不斷創新以保持競爭優勢。

下游對mRNA癌症疫苗和療法的需求正朝著多元化和精準化方向發展。大型綜合醫院和腫瘤中心優先考慮療效、安全性和個人化治療方法。患者和市場對創新有效治療方法的需求正在推動個人化mRNA疫苗客製化服務的成長，並促進精準醫療生態系統的發展。伴隨診斷和數據驅動決策的進步能夠實現更精準的患者分層，並改善臨床療效。生物技術和資訊技術的加速融合將使mRNA癌症療法的應用範圍擴展到更廣泛的癌症類型和更複雜的治療場景。

本報告旨在按地區/國家、類型和應用對全球 mRNA 癌症疫苗和治療市場進行全面分析，重點關注總收入、市場佔有率和主要企業的排名。

本報告以2024年為基準年，按銷售收入對mRNA癌症疫苗和療法市場規模、估值和預測進行了分析，並涵蓋了2020年至2031年的歷史數據和預測數據。定量和定性分析將幫助讀者制定mRNA癌症疫苗和療法的業務和成長策略，評估市場競爭，分析自身在當前市場中的地位，並做出明智的商業決策。

市場區隔

公司

  • Moderna Therapeutics
  • Pfizer
  • Translate Bio
  • BioNTech
  • Sangamo Therapeutics
  • Argos Therapeutics
  • In-Cell-Art
  • eTheRNA
  • Ethris
  • Tiba Biotechnology

按類型分類的細分市場

  • 腺癌
  • 黏液癌
  • 腺鱗癌

應用領域

  • 感染疾病
  • 癌症
  • 其他

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for mRNA Cancer Vaccines and Therapeutics was estimated to be worth US$ 9198 million in 2024 and is forecast to a readjusted size of US$ 11032 million by 2031 with a CAGR of 5.0% during the forecast period 2025-2031.

mRNA cancer vaccines and therapeutics are a novel class of tumor immunotherapy products based on messenger RNA (mRNA) technology. This approach involves designing and delivering mRNA molecules encoding tumor-associated antigens, enabling the patient's immune system to recognize and attack cancer cells, thereby achieving precise and effective anti-cancer responses. Compared to traditional cancer treatments, mRNA technology offers advantages such as shorter development cycles, flexible manufacturing, and strong potential for personalized customization, significantly enhancing treatment safety and efficacy. With rapid advances in biopharmaceuticals and gene editing technologies, mRNA cancer vaccines and therapeutics have emerged as a critical breakthrough in tumor immunotherapy, ushering cancer treatment into the era of precision immunotherapy.

The rising global cancer incidence and mortality rates drive urgent demand for innovative therapies to improve treatment outcomes and patient survival. Leading biopharmaceutical companies' annual reports highlight sustained investments in mRNA technology platforms, accelerating R&D of cancer vaccines and therapeutics while ensuring safety and efficacy. Government support through policies and funding fosters faster clinical trials and market access. The flexibility and personalization capabilities of mRNA technology meet diverse needs across cancer types and patient populations, showing great potential especially in hard-to-treat and recurrent cancers. Global aging populations and the spread of precision medicine concepts further fuel rapid market growth.

Despite vast market potential, challenges remain. Complex and costly R&D processes with extended validation periods increase development risks. Regulatory environments are evolving, with divergent approval standards and pathways across countries complicating international commercialization. High R&D and manufacturing costs contribute to expensive therapies, limiting patient access in some regions. Intense competition and complex interplay between traditional and emerging immunotherapies require companies to continuously innovate to sustain competitive advantage.

Downstream demand for mRNA cancer vaccines and therapeutics is moving toward diversification and precision. Major comprehensive hospitals and oncology centers prioritize efficacy, safety, and personalized treatment regimens. Patient and market demand for innovative and effective therapies drives growth in personalized mRNA vaccine customization services, fostering a precision medicine ecosystem. Advances in companion diagnostics and data-driven decision-making enable more precise patient stratification and improved clinical outcomes. Accelerated integration of biotech and information technology will expand mRNA cancer therapies to broader cancer types and more complex treatment scenarios.

This report aims to provide a comprehensive presentation of the global market for mRNA Cancer Vaccines and Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of mRNA Cancer Vaccines and Therapeutics by region & country, by Type, and by Application.

The mRNA Cancer Vaccines and Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding mRNA Cancer Vaccines and Therapeutics.

Market Segmentation

By Company

  • Moderna Therapeutics
  • Pfizer
  • Translate Bio
  • BioNTech
  • Sangamo Therapeutics
  • Argos Therapeutics
  • In-Cell-Art
  • eTheRNA
  • Ethris
  • Tiba Biotechnology

Segment by Type

  • Adeno Carcinomas
  • Mucinous Carcinomas
  • Adenosquamous Carcinomas

Segment by Application

  • Infectious Disease
  • Cancer
  • Others

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of mRNA Cancer Vaccines and Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of mRNA Cancer Vaccines and Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of mRNA Cancer Vaccines and Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 mRNA Cancer Vaccines and Therapeutics Product Introduction
  • 1.2 Global mRNA Cancer Vaccines and Therapeutics Market Size Forecast (2020-2031)
  • 1.3 mRNA Cancer Vaccines and Therapeutics Market Trends & Drivers
    • 1.3.1 mRNA Cancer Vaccines and Therapeutics Industry Trends
    • 1.3.2 mRNA Cancer Vaccines and Therapeutics Market Drivers & Opportunity
    • 1.3.3 mRNA Cancer Vaccines and Therapeutics Market Challenges
    • 1.3.4 mRNA Cancer Vaccines and Therapeutics Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global mRNA Cancer Vaccines and Therapeutics Players Revenue Ranking (2024)
  • 2.2 Global mRNA Cancer Vaccines and Therapeutics Revenue by Company (2020-2025)
  • 2.3 Key Companies mRNA Cancer Vaccines and Therapeutics Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies mRNA Cancer Vaccines and Therapeutics Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of mRNA Cancer Vaccines and Therapeutics
  • 2.6 mRNA Cancer Vaccines and Therapeutics Market Competitive Analysis
    • 2.6.1 mRNA Cancer Vaccines and Therapeutics Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by mRNA Cancer Vaccines and Therapeutics Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in mRNA Cancer Vaccines and Therapeutics as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Adeno Carcinomas
    • 3.1.2 Mucinous Carcinomas
    • 3.1.3 Adenosquamous Carcinomas
  • 3.2 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Type
    • 3.2.1 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global mRNA Cancer Vaccines and Therapeutics Sales Value, by Type (2020-2031)
    • 3.2.3 Global mRNA Cancer Vaccines and Therapeutics Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Infectious Disease
    • 4.1.2 Cancer
    • 4.1.3 Others
  • 4.2 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Application
    • 4.2.1 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global mRNA Cancer Vaccines and Therapeutics Sales Value, by Application (2020-2031)
    • 4.2.3 Global mRNA Cancer Vaccines and Therapeutics Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region
    • 5.1.1 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region (2020-2025)
    • 5.1.3 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region (2026-2031)
    • 5.1.4 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America mRNA Cancer Vaccines and Therapeutics Sales Value, 2020-2031
    • 5.2.2 North America mRNA Cancer Vaccines and Therapeutics Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe mRNA Cancer Vaccines and Therapeutics Sales Value, 2020-2031
    • 5.3.2 Europe mRNA Cancer Vaccines and Therapeutics Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific mRNA Cancer Vaccines and Therapeutics Sales Value, 2020-2031
    • 5.4.2 Asia Pacific mRNA Cancer Vaccines and Therapeutics Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America mRNA Cancer Vaccines and Therapeutics Sales Value, 2020-2031
    • 5.5.2 South America mRNA Cancer Vaccines and Therapeutics Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa mRNA Cancer Vaccines and Therapeutics Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa mRNA Cancer Vaccines and Therapeutics Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions mRNA Cancer Vaccines and Therapeutics Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions mRNA Cancer Vaccines and Therapeutics Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States mRNA Cancer Vaccines and Therapeutics Sales Value, 2020-2031
    • 6.3.2 United States mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States mRNA Cancer Vaccines and Therapeutics Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe mRNA Cancer Vaccines and Therapeutics Sales Value, 2020-2031
    • 6.4.2 Europe mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe mRNA Cancer Vaccines and Therapeutics Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China mRNA Cancer Vaccines and Therapeutics Sales Value, 2020-2031
    • 6.5.2 China mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China mRNA Cancer Vaccines and Therapeutics Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan mRNA Cancer Vaccines and Therapeutics Sales Value, 2020-2031
    • 6.6.2 Japan mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan mRNA Cancer Vaccines and Therapeutics Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea mRNA Cancer Vaccines and Therapeutics Sales Value, 2020-2031
    • 6.7.2 South Korea mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea mRNA Cancer Vaccines and Therapeutics Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia mRNA Cancer Vaccines and Therapeutics Sales Value, 2020-2031
    • 6.8.2 Southeast Asia mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia mRNA Cancer Vaccines and Therapeutics Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India mRNA Cancer Vaccines and Therapeutics Sales Value, 2020-2031
    • 6.9.2 India mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India mRNA Cancer Vaccines and Therapeutics Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Moderna Therapeutics
    • 7.1.1 Moderna Therapeutics Profile
    • 7.1.2 Moderna Therapeutics Main Business
    • 7.1.3 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions
    • 7.1.4 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Moderna Therapeutics Recent Developments
  • 7.2 Pfizer
    • 7.2.1 Pfizer Profile
    • 7.2.2 Pfizer Main Business
    • 7.2.3 Pfizer mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions
    • 7.2.4 Pfizer mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Pfizer Recent Developments
  • 7.3 Translate Bio
    • 7.3.1 Translate Bio Profile
    • 7.3.2 Translate Bio Main Business
    • 7.3.3 Translate Bio mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions
    • 7.3.4 Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Translate Bio Recent Developments
  • 7.4 BioNTech
    • 7.4.1 BioNTech Profile
    • 7.4.2 BioNTech Main Business
    • 7.4.3 BioNTech mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions
    • 7.4.4 BioNTech mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.4.5 BioNTech Recent Developments
  • 7.5 Sangamo Therapeutics
    • 7.5.1 Sangamo Therapeutics Profile
    • 7.5.2 Sangamo Therapeutics Main Business
    • 7.5.3 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions
    • 7.5.4 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Sangamo Therapeutics Recent Developments
  • 7.6 Argos Therapeutics
    • 7.6.1 Argos Therapeutics Profile
    • 7.6.2 Argos Therapeutics Main Business
    • 7.6.3 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions
    • 7.6.4 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Argos Therapeutics Recent Developments
  • 7.7 In-Cell-Art
    • 7.7.1 In-Cell-Art Profile
    • 7.7.2 In-Cell-Art Main Business
    • 7.7.3 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions
    • 7.7.4 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.7.5 In-Cell-Art Recent Developments
  • 7.8 eTheRNA
    • 7.8.1 eTheRNA Profile
    • 7.8.2 eTheRNA Main Business
    • 7.8.3 eTheRNA mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions
    • 7.8.4 eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.8.5 eTheRNA Recent Developments
  • 7.9 Ethris
    • 7.9.1 Ethris Profile
    • 7.9.2 Ethris Main Business
    • 7.9.3 Ethris mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions
    • 7.9.4 Ethris mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Ethris Recent Developments
  • 7.10 Tiba Biotechnology
    • 7.10.1 Tiba Biotechnology Profile
    • 7.10.2 Tiba Biotechnology Main Business
    • 7.10.3 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions
    • 7.10.4 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Tiba Biotechnology Recent Developments

8 Industry Chain Analysis

  • 8.1 mRNA Cancer Vaccines and Therapeutics Industrial Chain
  • 8.2 mRNA Cancer Vaccines and Therapeutics Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 mRNA Cancer Vaccines and Therapeutics Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 mRNA Cancer Vaccines and Therapeutics Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. mRNA Cancer Vaccines and Therapeutics Market Trends
  • Table 2. mRNA Cancer Vaccines and Therapeutics Market Drivers & Opportunity
  • Table 3. mRNA Cancer Vaccines and Therapeutics Market Challenges
  • Table 4. mRNA Cancer Vaccines and Therapeutics Market Restraints
  • Table 5. Global mRNA Cancer Vaccines and Therapeutics Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies mRNA Cancer Vaccines and Therapeutics Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies mRNA Cancer Vaccines and Therapeutics Product Type
  • Table 9. Key Companies Time to Begin Mass Production of mRNA Cancer Vaccines and Therapeutics
  • Table 10. Global mRNA Cancer Vaccines and Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in mRNA Cancer Vaccines and Therapeutics as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global mRNA Cancer Vaccines and Therapeutics Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global mRNA Cancer Vaccines and Therapeutics Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global mRNA Cancer Vaccines and Therapeutics Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global mRNA Cancer Vaccines and Therapeutics Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region (2020-2025) & (%)
  • Table 27. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions mRNA Cancer Vaccines and Therapeutics Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions mRNA Cancer Vaccines and Therapeutics Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions mRNA Cancer Vaccines and Therapeutics Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Moderna Therapeutics Basic Information List
  • Table 32. Moderna Therapeutics Description and Business Overview
  • Table 33. Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in mRNA Cancer Vaccines and Therapeutics Business of Moderna Therapeutics (2020-2025)
  • Table 35. Moderna Therapeutics Recent Developments
  • Table 36. Pfizer Basic Information List
  • Table 37. Pfizer Description and Business Overview
  • Table 38. Pfizer mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in mRNA Cancer Vaccines and Therapeutics Business of Pfizer (2020-2025)
  • Table 40. Pfizer Recent Developments
  • Table 41. Translate Bio Basic Information List
  • Table 42. Translate Bio Description and Business Overview
  • Table 43. Translate Bio mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in mRNA Cancer Vaccines and Therapeutics Business of Translate Bio (2020-2025)
  • Table 45. Translate Bio Recent Developments
  • Table 46. BioNTech Basic Information List
  • Table 47. BioNTech Description and Business Overview
  • Table 48. BioNTech mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in mRNA Cancer Vaccines and Therapeutics Business of BioNTech (2020-2025)
  • Table 50. BioNTech Recent Developments
  • Table 51. Sangamo Therapeutics Basic Information List
  • Table 52. Sangamo Therapeutics Description and Business Overview
  • Table 53. Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in mRNA Cancer Vaccines and Therapeutics Business of Sangamo Therapeutics (2020-2025)
  • Table 55. Sangamo Therapeutics Recent Developments
  • Table 56. Argos Therapeutics Basic Information List
  • Table 57. Argos Therapeutics Description and Business Overview
  • Table 58. Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in mRNA Cancer Vaccines and Therapeutics Business of Argos Therapeutics (2020-2025)
  • Table 60. Argos Therapeutics Recent Developments
  • Table 61. In-Cell-Art Basic Information List
  • Table 62. In-Cell-Art Description and Business Overview
  • Table 63. In-Cell-Art mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in mRNA Cancer Vaccines and Therapeutics Business of In-Cell-Art (2020-2025)
  • Table 65. In-Cell-Art Recent Developments
  • Table 66. eTheRNA Basic Information List
  • Table 67. eTheRNA Description and Business Overview
  • Table 68. eTheRNA mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in mRNA Cancer Vaccines and Therapeutics Business of eTheRNA (2020-2025)
  • Table 70. eTheRNA Recent Developments
  • Table 71. Ethris Basic Information List
  • Table 72. Ethris Description and Business Overview
  • Table 73. Ethris mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in mRNA Cancer Vaccines and Therapeutics Business of Ethris (2020-2025)
  • Table 75. Ethris Recent Developments
  • Table 76. Tiba Biotechnology Basic Information List
  • Table 77. Tiba Biotechnology Description and Business Overview
  • Table 78. Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in mRNA Cancer Vaccines and Therapeutics Business of Tiba Biotechnology (2020-2025)
  • Table 80. Tiba Biotechnology Recent Developments
  • Table 81. Key Raw Materials Lists
  • Table 82. Raw Materials Key Suppliers Lists
  • Table 83. mRNA Cancer Vaccines and Therapeutics Downstream Customers
  • Table 84. mRNA Cancer Vaccines and Therapeutics Distributors List
  • Table 85. Research Programs/Design for This Report
  • Table 86. Key Data Information from Secondary Sources
  • Table 87. Key Data Information from Primary Sources

List of Figures

  • Figure 1. mRNA Cancer Vaccines and Therapeutics Product Picture
  • Figure 2. Global mRNA Cancer Vaccines and Therapeutics Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global mRNA Cancer Vaccines and Therapeutics Sales Value (2020-2031) & (US$ Million)
  • Figure 4. mRNA Cancer Vaccines and Therapeutics Report Years Considered
  • Figure 5. Global mRNA Cancer Vaccines and Therapeutics Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by mRNA Cancer Vaccines and Therapeutics Revenue in 2024
  • Figure 7. mRNA Cancer Vaccines and Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Adeno Carcinomas Picture
  • Figure 9. Mucinous Carcinomas Picture
  • Figure 10. Adenosquamous Carcinomas Picture
  • Figure 11. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 12. Global mRNA Cancer Vaccines and Therapeutics Sales Value Market Share by Type, 2024 & 2031
  • Figure 13. Product Picture of Infectious Disease
  • Figure 14. Product Picture of Cancer
  • Figure 15. Product Picture of Others
  • Figure 16. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 17. Global mRNA Cancer Vaccines and Therapeutics Sales Value Market Share by Application, 2024 & 2031
  • Figure 18. North America mRNA Cancer Vaccines and Therapeutics Sales Value (2020-2031) & (US$ Million)
  • Figure 19. North America mRNA Cancer Vaccines and Therapeutics Sales Value by Country (%), 2024 VS 2031
  • Figure 20. Europe mRNA Cancer Vaccines and Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 21. Europe mRNA Cancer Vaccines and Therapeutics Sales Value by Country (%), 2024 VS 2031
  • Figure 22. Asia Pacific mRNA Cancer Vaccines and Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. Asia Pacific mRNA Cancer Vaccines and Therapeutics Sales Value by Region (%), 2024 VS 2031
  • Figure 24. South America mRNA Cancer Vaccines and Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. South America mRNA Cancer Vaccines and Therapeutics Sales Value by Country (%), 2024 VS 2031
  • Figure 26. Middle East & Africa mRNA Cancer Vaccines and Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 27. Middle East & Africa mRNA Cancer Vaccines and Therapeutics Sales Value by Country (%), 2024 VS 2031
  • Figure 28. Key Countries/Regions mRNA Cancer Vaccines and Therapeutics Sales Value (%), (2020-2031)
  • Figure 29. United States mRNA Cancer Vaccines and Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 30. United States mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 31. United States mRNA Cancer Vaccines and Therapeutics Sales Value by Application (%), 2024 VS 2031
  • Figure 32. Europe mRNA Cancer Vaccines and Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 33. Europe mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 34. Europe mRNA Cancer Vaccines and Therapeutics Sales Value by Application (%), 2024 VS 2031
  • Figure 35. China mRNA Cancer Vaccines and Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 36. China mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 37. China mRNA Cancer Vaccines and Therapeutics Sales Value by Application (%), 2024 VS 2031
  • Figure 38. Japan mRNA Cancer Vaccines and Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 39. Japan mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 40. Japan mRNA Cancer Vaccines and Therapeutics Sales Value by Application (%), 2024 VS 2031
  • Figure 41. South Korea mRNA Cancer Vaccines and Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 42. South Korea mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 43. South Korea mRNA Cancer Vaccines and Therapeutics Sales Value by Application (%), 2024 VS 2031
  • Figure 44. Southeast Asia mRNA Cancer Vaccines and Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 45. Southeast Asia mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 46. Southeast Asia mRNA Cancer Vaccines and Therapeutics Sales Value by Application (%), 2024 VS 2031
  • Figure 47. India mRNA Cancer Vaccines and Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 48. India mRNA Cancer Vaccines and Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 49. India mRNA Cancer Vaccines and Therapeutics Sales Value by Application (%), 2024 VS 2031
  • Figure 50. mRNA Cancer Vaccines and Therapeutics Industrial Chain
  • Figure 51. mRNA Cancer Vaccines and Therapeutics Manufacturing Cost Structure
  • Figure 52. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 53. Bottom-up and Top-down Approaches for This Report
  • Figure 54. Data Triangulation
  • Figure 55. Key Executives Interviewed